FDA warns against unapproved compounded weight-loss drugs, shares of Hims & Hers drop 3.2%.

The FDA issued warnings to telehealth companies and compounding pharmacies about the use of unapproved compounded weight-loss drugs, including versions of semaglutide, tirzepatide, and retatrutide. Hims & Hers Health shares fell 3.2% following the announcement. The FDA highlighted safety concerns such as dosing errors, fraudulent labeling, and improper shipping conditions. It emphasized that these compounded drugs are not FDA-approved and have not been evaluated for safety or effectiveness, signaling increased regulatory scrutiny ahead.